MV Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

MV Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2	Closed	-$264	–	1136
2025 Q1	$264	Hold	2	–	–	﹤0.01%	895
2024 Q4	$168	Hold	2	–	–	﹤0.01%	915
2024 Q3	$147	Sell	2 -1	-33%	-$75	﹤0.01%	921
2024 Q2	$206	Buy	3 +1	+50%	+$69	﹤0.01%	796
2024 Q1	$139	Buy	2 +1	+100%	+$69	﹤0.01%	748
2023 Q4	$72	Buy	+1	New	+$58	﹤0.01%	735

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

MV Capital Management's ITCI Position: Q2 2025 in Review

MV Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 2 shares — an estimated $264 sold.

MV Capital Management first reported a position in ITCI in Q4 2023 and held it in 6 quarters. The position peaked at $264 in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

MV Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
MV Capital Management sold 2 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $264.
MV Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 6 quarters.
MV Capital Management's Intra-Cellular Therapies Inc. position peaked at $264 in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on MV Capital Management's 13F filing for Q2 2025, filed 8 Aug 2025.